2024-513591-18-00已完成3 期
A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmenopausal women with osteoporosis
Shandong Boan Biotechnology Co. Ltd., Shandong Boan Biotechnology Co. Ltd.8 个研究点 分布在 3 个国家目标入组 460 人开始时间: 2024年11月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 460
- 试验地点
- 8
- 主要终点
- Information is not publicly available
研究概览
简要总结
All regions: To demonstrate equivalent efficacy between LY06006 and EU-Prolia, in terms of BMD in female participants with postmenopausal osteoporosis. For EU filing only: To demonstrate similar PD between LY06006 and EU-Prolia, in terms of the bone resorption marker sCTX in female participants with postmenopausal osteoporosis.
研究设计
- 分配方式
- Randomized
- 主要目的
- Transition Period
- 盲法
- Double (Monitor, Subject, Analyst, Investigator)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participant is ≥ 55 to ≤ 90 years of age inclusive, (upper age limit of 75 years inclusive, for participants in Czech Republic only), at the time of signing the informed consent.
- •Participant is an ambulatory postmenopausal woman (defined as lack of menstrual period for at least 12 months prior to Screening Visit, for which there is no other obvious pathological or physiological cause). - Serum FSH test can be done at the Screening Visit in case of uncertainty (for participants to be enrolled in the study in Bulgaria, FSH test is mandatory. FSH levels should be above the cut-off for postmenopausal women, as provided by the central laboratory). - Female participants who underwent bilateral oophorectomy (with or without hysterectomy) at least 6 weeks prior to the Screening Period are eligible to participate.
- •Participant is diagnosed with osteoporosis, with absolute BMD consistent with a T-score of ≤ -2.5 and ≥ -4.0 at the lumbar spine (L1-L4 region) as measured by DXA at the Screening Visit.
- •Participant has at least two lumbar vertebrae in L1-L4 region and one hip evaluable by DXA for BMD measurement at the Screening Visit.
- •Participant has body weight ≥ 50 kg and ≤ 90 kg at Screening.
- •Participant is able to read and understand, and willing to provide signed informed consent as described in Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
排除标准
- •Participant has a history of any severe or more than two moderate vertebral fractures as determined by central reading of lateral spine X-ray at Screening Visit.
- •Participant has a history and/or presence of hip fracture.
- •Participant has a history and/or presence of atypical femur fracture.
- •Participant presents with any active healing fracture, per assessment of the Investigator.
- •Participant has a history of bilateral hip replacement (unilateral is allowed if the other hip is evaluable by DXA).
- •Participant has history and/or presence of osteonecrosis of the external auditory canal.
- •Evidence of any of the following conditions which may affect BMD or interfere with the interpretation of the findings: a. Participant has a history of bone disease e.g., osteomalacia, osteopetrosis, Paget's disease, or osteogenesis imperfecta. b. Participant has a history of metabolic or other endocrinologic diseases such as Cushing's disease, hyperprolactinemia, hypopituitarism, acromegaly, malabsorption syndrome (or any gastrointestinal disorders associated with malabsorption, e.g., Crohn's disease and chronic pancreatitis). c. Participant has a history of chronic inflammatory diseases, obvious sclerosis, osteophytosis, severe scoliosis, or other degenerative changes due to other co-morbidities. d. Participant has a history or current hyperparathyroidism or hypoparathyroidism. Note: Mild non-clinically significant secondary hyperparathyroidism may be acceptable upon discussion with the Medical Monitor. e. Participant has current uncontrolled hyperthyroidism or hypothyroidism. Note: Participants with hypothyroidism who are on stable thyroid hormone replacement therapy may be allowed per the following criteria: • If TSH level is within normal range, the participant is eligible. • If TSH level is elevated (> upper limit of normal and ≤ 10.0 µIU/mL) and serum free T4 is within normal range, the participant is eligible. • If a marginally low TSH level results from therapy , the participant may be enrolled after discussion with the Medical Monitor. Note: 2) If TSH is marginally out of normal range, serum free T4 is within normal range, and there are no plausible medical conditions resulting in the abnormal TSH level, the participant may be enrolled with the approval from the Medical Monitor. f. Participant has other disease conditions where there is bone/joint involvement (e.g., rheumatoid arthritis, ankylosing spondylitis, gout, multiple myeloma, achondroplasia, bone metastases, renal osteodystrophy, osteomyelitis).
- •Participant has hypocalcemia (defined as albumin adjusted serum calcium level < 2.0 mmol/L [8.0 mg/dL]) or hypercalcemia (defined as albumin adjusted serum calcium levels >2.62 mmol/L [10.50 mg/dL]).
- •Participant has vitamin D deficiency (defined as 25-hydroxy vitamin D level < 20 ng/mL [< 50 nmol/L]). Note: Oral replenishment of vitamin D is permitted at the discretion of the Investigator and in accordance with local standard of care during the Screening Period. Participants can be enrolled if a repeat test (post supplementation) prior to enrollment shows corrected 25-hydroxy vitamin D level ≥ 20 ng/mL (≥ 50 nmol/L).
- •Use of any of the below medications that can affect BMD: a. Denosumab used at any time prior to Screening Visit. b. Oral bisphosphonates at any dose for osteoporosis treatment: • Used for > 3 years cumulatively at Screening Visit. • At any dose used within 1 year prior to Screening Visit (if ≤ 3 years of use cumulatively). c. Intravenous bisphosphonate at any dose within 5 years prior to Screening Visit. d. PTH or PTH analogues at any dose within 2 years prior to Screening Visit. e. Systemic HRT (oral or transdermal estrogen), SERMs, tibolone, aromatase inhibitors, or androgens at any dose within 1 year prior to Screening Visit. Note: Exceptionally, non-systemic vaginal estrogen treatment is permitted. f. Calcitonin, or its derivatives, and calcimimetics (such as cinacalcet or etelcalcetide) at any dose within 12 months prior to Screening Visit. g. Calcitriol, paricalcitol, alfacalcidol, or eldecalcitol within 3 months of the Screening Visit. h. Fluoride or strontium at any dose at any time prior to Screening Visit. i. Romosozumab or cathepsin K inhibitors received at any time prior to Screening Visit. j. Systemic glucocorticoids (≥ 5 mg prednisone or equivalent per day for more than 10 days or cumulative ≥ 50 mg) within 3 months prior to Screening Visit. k. If the participant is currently on proton pump inhibitors (PPIs) and will continue to use PPIs while on the study, the total of the chronic use of PPIs exceeds 24 months or had past use of PPIs for more than 24 month AND within 3 months prior to Screening Visit. If the participant is currently on proton pump inhibitors (PPIs) and will continue to use PPIs while on the study, the total of the chronic use of PPIs exceeds 24 months or had past use of PPIs for more than 24 month AND within 3 months prior to Screening Visit.
- •Participant is receiving or has received another investigational product within 1 month or 5 half-lives of the other investigational product, whichever is longer, before study intervention administration in this study.
- •Participant has any malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years.
- •Participant has DXA measurements where: a. Height, weight, or girth measurements may preclude accurate DXA measurements in the Investigator’s opinion. b. BMD absolute value is consistent with a T-score < -4.0 at the total hip or femoral neck.
- •Participant has severe renal impairment (defined as participant in dialysis or with an eGFR < 30 mL/min per MDRD formula).
- •Participant has inadequate hepatic function (ALT and/or AST ≥ 2 × ULN).
- •Participant presents with clinically significant leukopenia, neutropenia, or anemia as judged by the Investigator.
- •Participant has a known intolerance to calcium or vitamin D supplements.
- •Participant has a history of prescription drug abuse or any illicit drug use within 6 months prior to Screening Visit.
- •Participant has a history of alcohol abuse (defined as consuming more than 3 drinks on any day or more than 7 drinks per week) according to medical history within 6 months prior to Screening Visit.
- •Participant is a smoker or has used nicotine and nicotine-containing products within 12 months of Screening Visit.
- •Participant has a known sensitivity to mammalian cell-derived drug products and/or a history of hypersensitivity to any of the ingredients of study interventions.
- •Participant is immunosuppressed for any reason.
- •Participant has known history of liver cirrhosis.
- •Participant has any other conditions including clinically significant medical conditions/disorders/diseases, psychiatric status, or laboratory abnormalities that in the opinion of the Investigator might interfere with the participant’s ability to participate in the study, would pose a risk to the participant’s safety, or interfere with the study evaluation, procedure, or completion.
- •Participant has known history of hepatitis B, hepatitis C, or HIV infection, or an active infection including, but not limited to SARS-CoV-2, tests positive for hepatitis B (positive HBsAg, positive anti-HBc with negative anti-HBs), hepatitis C (hepatitis C antibody), or HIV antibody during the Screening Period.
- •Participant has oral or dental conditions: a. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw. b. Active dental or jaw condition which requires oral surgery. c. Invasive dental procedure planned during the study or within the past 6 months (e.g., tooth extraction, dental implants, oral surgery). d. Non-healed dental or oral surgery. e. Active periodontal disease. f. Poor oral hygiene.
- •Participant has a history of major surgery within 8 weeks prior to the Screening Period or planned, anticipated major surgery during the study.
- •Participant has a history and/or presence of significant cardiac disease or ECG abnormalities indicating significant risk for participating in the study as judged by the Investigator.
- •Participant shows contraindications to denosumab therapy (e.g., hypocalcemia), or calcium or vitamin D supplementation before starting study intervention administration.
- •Participant requires ongoing use of any osteoporosis treatment (other than calcium and vitamin D supplements).
结局指标
主要结局
Information is not publicly available
Information is not publicly available
次要结局
- %CfB in lumbar spine BMD at Month 6
- %CfB in total hip BMD at Months 6 and 12
- %CfB in femoral neck BMD at Months 6 and 12
- %CfB in sCTX at Months 0.5, 1, 2, 3, 6, 9, and 12
- %CfB in sP1NP at Months 1, 6, and 12
- AEs, including SAEs
- Vital signs
- Physical and dental examination
- Clinical laboratory tests (hematology, clinical chemistry, and urinalysis)
- 12-lead ECG
- Injection site reaction assessment
- Serum drug concentrations at baseline and at Months 0.5, 1, 2, 3, 6, 9, and 12
- Incidence of ADAs at baseline and at Months 0.5, 1, 2, 3, 6, 9, and 12
- Incidence of NAbs at baseline and at Months 0.5, 1, 2, 3, 6, 9, and 12
- %CfB (Month 12) in sCTX at Month 18
- %CfB (Month 12) in sP1NP at Month 18
- Serum drug concentrations at baseline (Month 12) and Months 15 and 18
- Incidence of ADAs at baseline (Month 12), and Months 15 and 18
- Incidence of NAbs at baseline (Month 12) and at Months 15 and 18
研究者
Ying Dong
Scientific
Shandong Boan Biotechnology Co. Ltd.
研究点 (8)
Loading locations...
相似试验
招募中
3 期
Protocol Title: Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%)2024-512075-12-00Pfizer Inc.18
招募中
2 期
Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MMX is for patients with idiopathic bile acid diarrhoea (BAD), randomly allocated to 2 different dose regimens of the active product or to the inactive placebo formulation.2024-511993-55-00Cosmo Technologies Limited120
进行中（未招募）
1 期
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)NCT07300085Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)710
招募中
1 期
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT2024-519010-31-00Fondazione Melanoma Onlus80
招募中
3 期
5% KOH solution vs placebo treatment of actinic keratosis with different treatment durationActinic keratosis2024-514277-21-00INFECTOPHARM Arzneimittel und Consilium GmbH630